Shares in Mologen AG jumped 17 percent to a 52-week high Monday on news that the company's DNA-based cancer immunotherapy, MGN1703, hit the primary endpoint, a prolongation of progression-free survival (PFS), in a Phase II trial in patients with metastatic colorectal cancer (CRC). Read More
Scientists have reported they were able to improve memory in patients with amnestic mild cognitive impairment – a neurological condition somewhere between normal age-related memory loss and outright dementia that often progresses to Alzheimer's disease – by treating them with low doses of the anti-epileptic drug Keppra (levetiracetam, from Brussels, Belgium-based UCB SA). Read More
A Series C financing round of $10 million will support clinical studies and commercial launch of Regentis Biomaterials Ltd.'s knee cartilage regeneration product, GelrinC, in Europe, including a sales force and a postmarket study. Read More
• Biovest International Inc., a subsidiary of Accentia Biopharmaceuticals Inc., both of Tampa, Fla., said it plans to file a marketing authorization application with the European Medicines Agency (EMA) for BiovaxID, its personalized cancer vaccine in follicular non-Hodgkin's lymphoma, following pre-filing meetings with the EMA. Read More
• Fibrocell Science Inc., of Exton, Pa., said it submitted to the FDA its Phase II protocol for testing lead therapy azficel-T in improving the range of motion, function and flexibility in patients with existing restrictive burn scars. Azficel-T, an autologous cell therapy, previously gained approval as LaViv for reducing the appearance of moderate to severe nasolabial fold wrinkles. Read More
• Stiefel, of Research Triangle Park, N.C., part of GlaxoSmithKline plc, said the FDA approved a new drug application for Fabior (tazarotene) foam 0.1 percent, a topical formulation of a retinoid to treat acne vulgaris in patients 12 years and older. Read More
